Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs

Tyrosine kinase inhibitors (TKIs), which have revolutionized cancer therapy over the past 15 years, are limited in their clinical application due to serious side effects. Therefore, we converted two approved TKIs (sunitinib and erlotinib) into 2-nitroimidazole-based hypoxia-activatable prodrugs. Kin...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:ChemMedChem
Auteurs principaux: Karnthaler-Benbakka, Claudia, Groza, Diana, Koblmüller, Bettina, Terenzi, Alessio, Holste, Katharina, Haider, Melanie, Baier, Dina, Berger, Walter, Heffeter, Petra, Kowol, Christian R., Keppler, Bernhard K.
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151264/
https://ncbi.nlm.nih.gov/pubmed/27706901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cmdc.201600417
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires